CLINICAL_TRIALS ClinicalTrials.gov record update

TCR-αβ+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02508038
Title field or adapter rule: {'original_value': 'TCR-αβ+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-11-01T01:03:13.059270+00:00
Published At: 2026-10-27T00:00:00+00:00
Record Updated At: 2026-10-27
Source Retrieved At: 2026-11-01T01:03:12.230707+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Hodgkin Lymphoma", "Non-Hodgkin Lymphoma", "Myelodysplastic Syndrome", "Myeloproliferative Syndrome", "Rhabdomyosarcoma", "Ewing Sarcoma", "Primitive Neuroectodermal Tumor", "Osteosarcoma", "Neuroblastoma"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-27", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT02508038"
protocolSection.identificationModule.officialTitle: "TCR-\u03b1\u03b2+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

{'armGroupLabels': ['TCRαβ+/CD19+ depleted Haploidentical HSCT+ Zoledronate'], 'description': 'Patients with high-risk leukemia will receive myeloablative conditioning. All other patients will undergo a reduced-intensity conditioning with ATG, Fludarabine, Thiotepa and Melphalan followed by transplant with a KIR/KIR (Killer cell immunoglobulin-like recetptor) ligand mismatched haploidentical donor peripheral blood stem cell graft depleted of TCRab+ cells and CD19+ cells using the CliniMACS System.', 'name': 'TCRαβ+/CD19+ depleted Haploidentical HSCT', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['TCRαβ+/CD19+ depleted Haploidentical HSCT+ Zoledronate'], 'description': 'Given IV. Patients will receive five doses of Zoledronate (each 1.25 mg/m2 at a 28 day interval) following transplant.', 'name': 'Zoledronate', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.